Teva Gets What It Wants – Allergan Generics, Not Mylan
This article was originally published in The Tan Sheet
Executive Summary
Teva’s $40.5 billion acquisition of Allergan Generics will solidify Teva as the world’s leading generics company with $26 billion in combined revenues and 320 ANDAs pending at FDA.
You may also be interested in...
Bausch + Lomb Turns To Familiar Face As CEO, Brent Saunders
Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Bausch + Lomb Taps A Familiar Face, Brent Saunders, As Next CEO
Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Pharma Dealmaker Saunders Includes Wellness Space In Acquisition Group’s Investment Targets
Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.